These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1402660)

  • 21. Engineered IgG1-Fc--one fragment to bind them all.
    Lobner E; Traxlmayr MW; Obinger C; Hasenhindl C
    Immunol Rev; 2016 Mar; 270(1):113-31. PubMed ID: 26864108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applications for an engineered Protein-G variant with a pH controllable affinity to antibody fragments.
    Bailey LJ; Sheehy KM; Hoey RJ; Schaefer ZP; Ura M; Kossiakoff AA
    J Immunol Methods; 2014 Dec; 415():24-30. PubMed ID: 25450256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody Fc engineering improves frequency and promotes kinetic boosting of serial killing mediated by NK cells.
    Romain G; Senyukov V; Rey-Villamizar N; Merouane A; Kelton W; Liadi I; Mahendra A; Charab W; Georgiou G; Roysam B; Lee DA; Varadarajan N
    Blood; 2014 Nov; 124(22):3241-9. PubMed ID: 25232058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
    Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences.
    Sibéril S; Dutertre CA; Boix C; Bonnin E; Ménez R; Stura E; Jorieux S; Fridman WH; Teillaud JL
    Immunol Lett; 2006 Aug; 106(2):111-8. PubMed ID: 16797726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Removal of a C-terminal serine residue proximal to the inter-chain disulfide bond of a human IgG1 lambda light chain mediates enhanced antibody stability and antibody dependent cell-mediated cytotoxicity.
    Shen Y; Zeng L; Zhu A; Blanc T; Patel D; Pennello A; Bari A; Ng S; Persaud K; Kang YK; Balderes P; Surguladze D; Hindi S; Zhou Q; Ludwig DL; Snavely M
    MAbs; 2013; 5(3):418-31. PubMed ID: 23567210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
    Newman R; Hariharan K; Reff M; Anderson DR; Braslawsky G; Santoro D; Hanna N; Bugelski PJ; Brigham-Burke M; Crysler C; Gagnon RC; Dal Monte P; Doyle ML; Hensley PC; Reddy MP; Sweet RW; Truneh A
    Clin Immunol; 2001 Feb; 98(2):164-74. PubMed ID: 11161972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
    Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
    J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity.
    Huang J; Shibaguchi H; Zhao J; Luo N; Kuroki M; Kinugasa T; Hirose Y; Yamada H; Kuroki M
    Anticancer Res; 2006; 26(2A):1057-63. PubMed ID: 16619506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant thyroid peroxidase-specific Fab converted to immunoglobulin G (IgG) molecules: evidence for thyroid cell damage by IgG1, but not IgG4, autoantibodies.
    Guo J; Jaume JC; Rapoport B; McLachlan SM
    J Clin Endocrinol Metab; 1997 Mar; 82(3):925-31. PubMed ID: 9062508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge.
    Stevenson GT; Pindar A; Slade CJ
    Anticancer Drug Des; 1989 Mar; 3(4):219-30. PubMed ID: 2930624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
    Natsume A; Wakitani M; Yamane-Ohnuki N; Shoji-Hosaka E; Niwa R; Uchida K; Satoh M; Shitara K
    J Immunol Methods; 2005 Nov; 306(1-2):93-103. PubMed ID: 16236307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Attack on neoplastic cell membranes by therapeutic antibody.
    Stevenson GT
    Mol Cell Biochem; 1989 Nov 23-Dec 19; 91(1-2):33-8. PubMed ID: 2622456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric univalent antibodies for treating lymphoid malignancies.
    Stevenson GT; Cole VM; Summerton J; Watts HF
    Med Oncol Tumor Pharmacother; 1984; 1(4):275-8. PubMed ID: 6544904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
    J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: inhibition of IgG-mediated complement activation.
    Russell MW; Reinholdt J; Kilian M
    Eur J Immunol; 1989 Dec; 19(12):2243-9. PubMed ID: 2606139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
    Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
    Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Pereira NA; Chan KF; Lin PC; Song Z
    MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
    Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
    Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.